Polyethylene glycol-modified pigment epithelial-derived factor: New prospects for treatment of retinal neovascularization

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 1, 2012, Pages 131-139

  Bai, Yu Jing ^a   Huang, Lv Zhen ^a   Xu, Xiao Lei ^b   Du, Wei ^a   Zhou, Ai Yi ^a   Yu, Wen Zhen ^a   Li, Xiao Xin ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Dong Xiao Jiang Beijing Science and Technology Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN; PIGMENT EPITHELIUM DERIVED FACTOR; PROPYLENE GLYCOL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RETINAL LEVEL; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; RETINA BLOOD FLOW; RETINA NEOVASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CHOROIDAL NEOVASCULARIZATION; EYE PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RETINA; RETINAL NEOVASCULARIZATION; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862492038     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.192575     Document Type: Article

References (30)

1. Abuchowski A, McCoy JR, Palczuk NC, van Es T, and Davis FF (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252:3582-3586. (Pubitemid 8116088)
2. Barnstable CJ and Tombran-Tink J (2004) Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 23:561-577. (Pubitemid 39078362)
3. Bouck N (2002) PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 8:330-334.
4. Chappelow AV and Kaiser PK (2008) Neovascular age-related macular degeneration: potential therapies. Drugs 68:1029-1036. (Pubitemid 351693673)
5. Chen J and Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10:133-140. (Pubitemid 46440629)
6. Cheung N, Mitchell P, and Wong TY (2010) Diabetic retinopathy. Lancet 376:124-136.
7. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, and Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245-248. (Pubitemid 29329995)
8. Drack A (2006) Retinopathy of prematurity. Adv Pediatr 53:211-226.
9. Drake WM and Trainer PJ (2003) Clinical use of pegvisomant for the treatment of acromegaly. Treat Endocrinol 2:369-374. (Pubitemid 37462236)
10. Gao G, Li Y, Fant J, Crosson CE, Becerra SP, and Ma JX (2002) Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes 51:1218-1225. (Pubitemid 34438372)
11. Gariano RF (2010) Special features of human retinal angiogenesis. Eye (Lond) 24:401-407.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, and VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. New Eng J Med 351:2805-2816. (Pubitemid 40051904)
13. Graham ML (2003) Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 55:1293-1302.
14. Harris JM and Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
15. He SS, Shi HS, Yin T, Li YX, Luo ST, Wu QJ, Lu L, Wei YQ, and Yang L (2012) AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits lewis lung carcinoma growth in mice. Oncol Rep 27:1142-1148.
16. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, et al. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New Engl J Med 343:1673-1680.
17. Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, and Kobayashi AL (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. New Engl J Med 316:589-596. (Pubitemid 17024481)
18. Huang L, Xu Y, Yu W, Li Y, Chu L, Dong J, and Li X (2010) Effect of Robo1 on retinal pigment epithelial cells and experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 51:3193-3204.
19. Mousa SA and Mousa SS (2010) Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs 24:183-194.
20. Pai SS, Tilton RD, and Przybycien TM (2009) Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. AAPS J 11:88-98.
21. Park K, Jin J, Hu Y, Zhou K, and Ma JX (2011) Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. Am J Pathol 178:688-698.
22. Parveen S and Sahoo SK (2006) Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 45:965-988. (Pubitemid 44436001)
23. Qiu LY and Bae YH (2006) Polymer architecture and drug delivery. Pharm Res 23:1-30. (Pubitemid 43214657)
24. Reddy KR (2000) Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 34:915-923.
25. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, and D'Amore PA (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-111. (Pubitemid 24046832)
26. Streck CJ, Zhang Y, Zhou J, Ng C, Nathwani AC, and Davidoff AM (2005) Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J Pediatr Surg 40:236-243. (Pubitemid 40143565)
27. Tombran-Tink J, Chader GG, and Johnson LV (1991) PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 53:411-414.
28. Wedemeyer H, Wiegand J, Cornberg M, and Manns MP (2002) Polyethylene glycolinterferon: current status in hepatitis C virus therapy. J Gastroenterol Hepatol zvol17 (Suppl 3):S344-S350.
29. Yowell SL and Blackwell S (2002) Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 28 (Suppl A):3-6. (Pubitemid 34679211)
30. Yu WZ, Li XX, She HC, He PY, Dong JQ, Rui M, and Ma DL (2003) Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res 35:239-246. (Pubitemid 36980792)